# Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

> **NCT00923091** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 2689 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo
- **DRUG:** Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo
- **DRUG:** olmesartan medoxomil + amlodipine + hydroclororthiazide
- **DRUG:** olmesartan medoxomil + amlodipine + hydroclororthiazide
- **DRUG:** olmesartan medoxomil + amlodipine + hydroclororthiazide
- **DRUG:** olmesartan medoxomil + amlodipine
- **DRUG:** olmesartan medoxomil + amlodipine
- **DRUG:** olmesartan medoxomil + amlodipine

## Key facts

- **NCT ID:** NCT00923091
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-01
- **Final completion:** 2011-03
- **Target enrollment:** 2689 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923091, "Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00923091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*